Over the last two decades, gene transfer experiments for the treatment of inherited or acquired diseases have mainly been performed in mice. While mice provide proof of principle and allow testing of a variety of therapeutic modalities, mouse models have some limitations, as only short-term experiments can be performed, their homogenous genetic background is unlike humans, and the knockout models do not always faithfully represent the human disease. Naturally occurring large animal models of human genetic diseases have become increasingly important despite the costs and the extensive clinical attention they require because of their similarities to human patients. Large animals are reasonably outbred, long lived allowing for longitudinal studies, are more similar in size to a neonate or small child providing an opportunity to address issues related to scaling up therapy, and many physiological parameters including the immune system are more similar to those in humans versus those in mice.
Introduction
Most diseases that are currently viewed as candidates for gene therapy are caused by mutations resulting in the absence of a particular protein (eg enzyme deficiencies) or are the result of dysregulation/failure of controlled cell growth (ie cancer). The most common current gene transfer approach to providing tissues with a therapeutic protein is to administer normal cDNA to express the missing protein, or in the case of cancer to either provide 'suicide genes' or antitumor factors. These approaches usually involve using a viral vector to transfer the cDNA, which may either integrate into the chromosomal DNA of the patient's cells or may remain episomal, or both. A vast number of experiments have been performed in mice and other species to develop clever methods of gene transfer. However, as has been seen in recent human clinical trials, 1, 2 there are important safety concerns, which need to be addressed. Therefore, gene transfer studies with statistically and rationally meaningful outcomes need to be evaluated in models that closely resemble the human diseases.
Mice have been invaluable for the study of gene transfer methods and gene therapy of inherited diseases. They are inexpensive to keep, their generation time is short, and they have large litters. Today's transgenic technologies allow the development of almost any monogenetic disease model in the mouse and the various mouse strains are highly inbred, providing uniform conditions in which experiments can be easily reproduced and statistical significance achieved. 3 However, mouse models may fail to faithfully mirror the human disease 4,5 and longitudinal studies are not possible because of their short lifespan. Thus, large animal models of human genetic diseases complement the murine studies because they have a longer lifespan, are more similar in size to a neonate or child, their background genetic heterogeneity is similar to that of humans, and they are genetically more closely related to humans than mice. 6, 7 Scaling up issues can also be addressed in large animals; there is a 1000-fold size difference between a mouse and newborn child's brain but only 10-fold between a small dog and a neonatal human. Also, because of their longevity and size, more samples from an individual over time can be obtained to determine long-term efficacy and safety of a given therapy. Large animal models clearly represent an important step in the preclinical evaluation of human-directed gene transfer protocols. Dogs and cats are the most commonly used species. Some larger species have been used in the past to better understand genetic diseases, but considerations of size, housing, and reproduction have limited their use in treatment protocols. Sheep 8, 9 and non-human primates 10 are often used for the development of gene transfer techniques, gene marking studies, and assessment of safety, but despite the existence of genetic diseases in these species, they have not yet been used for treatment trials.
Other large animal models, such as pigs or horses, are almost exclusively used to study treatment of induced diseases, such as cardiovascular disease and arthritis, respectively. The list of large animal models of human diseases has become quite long and continues to increase. 11 Examples of large animal models used for gene therapy are highlighted below.
Canine models
The dog is the most widely used experimental large animal for therapeutic gene transfer studies of naturally occurring genetic diseases. To date, over 350 genetic diseases have been described in the dog, many of which are analogous to human genetic diseases. 12, 13 Dogs have been invaluable for the understanding of both disease pathogenesis and a variety of therapies. 12 Over 58% of genetic diseases present in the dog are true orthologues of human diseases caused by mutations in the same genes. 14 In addition to the obvious longevity and similarity in size to a small child, many parts of the canine immune system are much more similar to those of the human than the murine immune system. 15 The wide diversity of dog breeds and breeding practices have led to a large number of distinct and isolated genetic populations. This combined with exponential advances in canine genetics in recent years has led to the identification and characterization of numerous canine genetic disorders, many of which exist in research colonies. 16, 17 Mucopolysaccharidosis VII (MPS VII), caused by deficient activity of beta-glucuronidase (GUSB), was first described in a child in 1973. 18 This lysosomal storage disease has multisystemic manifestations including organomegaly, and skeletal, central nervous system (CNS), cardiovascular, and ocular abnormalities. 19 The first animal model of MPS VII was described from German shepherd dogs in 1984 at the University of Pennsylvania. 20 The murine 21 and feline MPS VII models were subsequently described. 22 -24 For the murine, canine, and feline models, the cDNA sequences are known, and the mutations have been identified. 22, 25, 26 Treatment of lysosomal storage diseases is based on crosscorrection; the ability of the normal enzyme to be taken up by deficient cells. 27 Intravenous delivery of recombinant adeno-associated virus (rAAV) vectors in MPS VII mice resulted in substantial correction of disease and included normalization or significant improvements of body growth, retinal morphology and function, auditory deficits, skeletal abnormalities, and lifespan with stable enzyme activity for at least 1 year post treatment. 28 Insights from this experiment led to testing intravenous retroviral (RV) vectors in neonatal dogs, which showed that the natural hepatocellular division in the canine neonatal period was sufficient for significant RV integration. 29 This preliminary step was followed by neonatal, intravenous, RV gene therapy in dogs and mice with MPS VII, which yielded impressive clinical and pathological results.
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The series of canine experiments involved treatment of dogs at days 2 -3 of life. These dogs, treated with the canine cDNA, have had stable serum GUSB activity of between 40 and 6000% of normal for up to the current 5 years. Important clinical signs of disease, such as cardiac abnormalities, were absent or minimal. 32 There was marked improvement in the growth of treated dogs, and the skeletal disease was improved in the limbs. 30, 31 The dogs have remained ambulatory to 5 years, versus untreated affected dogs, which are unable to stand or walk by the age of 6 months. Corneal clouding has been absent or very mild in all treated dogs. To date, no offspring, of over 180 evaluated, possess the transgene, and no transgene has been detected in sperm from the treated males (Haskins, unpublished data) . In addition to the transduction of up to 20% of hepatocytes, preliminary results showed this treatment to have also transduced hematopoetic stem cells, as peripheral white blood cells have remained vectorand GUSB expression-positive for 4.5 years. 34 In a preliminary result from MPS VII dogs treated later, at 7 weeks of age, with and without hepatocyte growth factor, serum GUSB activity was stable at 14 -83% of normal, which was impressive, but little reduction in clinical disease was seen.
The percent of normal enzyme activity in peripheral white blood cells containing vector sequence was very low 35 compared to the neonatally treated dogs, which may help explain the apparent superiority of the earlier treatment. 46 This resulted in amelioration of the disease demonstrated by normal blood coagulation and hemostatic measurements. However, as is typical with adenoviral vectors, the activity then declined due to an immune response. 46 The experiments with the most encouraging results were those using serotype 2 AAV vectors delivered by percutaneous injections into skeletal muscle. Five hemophilia B dogs with a missense mutation were treated with the canine cDNA and showed stable (417 months) vector dose-dependent partial correction of the whole blood clotting time and, at higher doses, of the activated partial thromboplastin time. 47 Treating hemophilia B dogs carrying a null mutation for FIX resulted in the induction of inhibitory anti-canine FIX antibodies. However, treatment with a combination of gene transfer and transient immune modulation resulted in sustained expression (48 months) at levels sufficient for partial correction of coagulation parameters. 48 The intramuscular approach was shown to be dose-dependent. 49 However, large doses of vector in single sites produced anti-FIX antibodies. 50 A novel alternate approach used an intravascular isolated limb delivery technique to achieve extensive transduction of most of the muscle in the dog limb, resulting in long-term (43 years, with observation ongoing), robust FIX expression (circulating levels of 4 -14% of normal), and essentially complete correction of the bleeding disorder.
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Intravenous and portal vein administration of AAV vectors producing transduction of hepatocytes resulted in up to 14% of normal canine FIX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect. 52 -55 However, one dog with a null mutation showed transient expression (4 weeks) and the development of neutralizing anti-canine FIX inhibitory antibodies. 55 In a third approach, an RV vector was administered intravenously to three newborn hemophilia B dogs, resulting in hepatocyte transduction, 12 -36% of normal canine FIX levels, and improved coagulation tests. Congenital stationary night blindness was first described in the Briard breed and is characterized by early retinal degeneration with clinical signs ranging from normal day vision to complete blindness. 57 The disease is orthologous to Leber congenital amaurosis in humans and is caused by a 4-bp deletion in the RPE65 gene in dogs 58 that truncates the normal protein, resulting in undetectable levels of the visual pigment rhodopsin, which is required for normal vision. Briard dogs with a mutation in RPE65 have early and severe visual impairment. Histopathological examination of the retinas of dogs homozygous for the RPE65 mutation showed prominent inclusions in the RPE and a slightly abnormal morphology of rods early in life, with slowly progressive degeneration of the photoreceptors. 59 AAV vectors were administered subretinally or intravitreally to three affected dogs. 60 This approach placed the vector in direct contact with the cells of the RPE. The treated dogs were evaluated and compared to untreated affected dogs using electroretinography (ERG) and by setting up obstacle courses in subdued lighting. ERG testing showed improvement in treated eyes compared with the same eyes prior to treatment and when compared with the untreated contralateral eye. As expected, retinal function did not completely return to normal, as the injection of vector targeted only about 35% of the retina. Injection of the vector into the vitreous body did not improve retinal function. 60 Importantly, the results of qualitative (behavioral) assessments of visual function conducted 4 months after treatment were consistent with the ERG findings. The treated dogs were scored as 'normally sighted' under room lighting: they consistently avoided objects placed directly in front of them and on the treated side, but failed to avoid objects placed on the untreated side. 60 The oldest treated animal has remained visually stable for 5 years (Acland, personal communication).
Neoplasia
Many cancers in the dog occur at higher frequencies in certain breeds and can be traced through specific lineages within a breed suggesting hereditary components. Other cancers, such as mammary cancers, are very common but do not have a specific breed predilection. Several clinical trials have been attempted to treat hereditary or spontaneous forms of canine neoplasia. 61 -66 Experiments in the treatment of canine oral melanomas are highlighted here because, despite some differences, the overall biological behavior of malignant melanoma is very similar in dogs and humans, making the dog an ideal model for development of therapy. Oral melanomas in the dog are almost always malignant. Dogs with stage III melanoma have a short median survival Large animal models and gene therapy M Casal and M Haskins time of 4 -5 months, and without surgical resection the tumor will lead to death because 85 -90% of the tumors metastasize. 67 In a clinical trial for canine oral melanoma, liposomes conjugated to Fas-ligand (FasL) DNA were injected directly into the tumors to induce apoptosis. 61 Tumor regression of 12.5 -58% was observed in three of five patients (one dog showed stable disease, and tumor size could not be evaluated in the fifth dog). No local or systemic adverse effects were observed over the course of the 7-day observation period. At 7 days after intratumoral therapy, the study dogs were given standard treatment for their tumors (surgery, radiation, or palliation). Two dogs went into complete remission until they died of unrelated causes at 24 and 44 weeks post therapy. Two dogs achieved partial remission; one died 13 weeks later of an unrelated cause. The disease progressed in the other dog 42 weeks after treatment, was surgically debulked and the dog lived for 82 weeks after gene therapy, at which time it died of its melanoma. 61 Fas-L expression in tumor cells obtained from those dogs with the best responses to therapy was present but was not detected in those cells from dogs with little or no response to treatment. 61 In another experiment, 26 dogs with malignant melanoma received intratumoral injections of lipid-complexed plasmid DNA encoding a bacterial superantigen and one of two cytokines (IL-2 or GM-CSF). 63 No side effects were noted and partial or complete remission was achieved in 12/26 treated dogs. Interestingly, the authors observed high levels of antitumor cytotoxic T-cell activity in the peripheral blood indicating that local administration of the vector may have produced a systemic effect. 63 
Feline models
Cats are of particular interest for neurological disorders, as the cat brain has been very well characterized both functionally and physiologically. The anatomy of the cat brain is also more similar to that of a human than that of a mouse.
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Feline alpha-mannosidosis (AMD) 70, 71 Mannosidosis is a glycoprotein storage disease caused by a deficiency of lysosomal acidic alpha-mannosidase and results in the lysosomal accumulation of mannose-rich oligosaccharides. The mutation in the feline model is a 4 base pair deletion, leading to a frame shift and premature termination codon. 72 Affected cats exhibit generalized action tremors, intention tremors of the head and neck, loss of balance, nystagmus, spinal ataxia, and dysmetria, and histologically have widespread neuronal storage. All signs are progressive and euthanasia is usually performed between 18 and 20 weeks of age for humane reasons. As with other lysosomal storage diseases, enzyme released from genetically corrected cells can be taken up by mutant cells, and a small amount of normal enzyme is sufficient to correct storage lesions. Heterologous bone marrow transplantation yielded dramatic results in the treatment of the CNS disease of cats with AMD, even though therapy was begun when mild clinical signs were present. 73 To test the efficacy of gene transfer, 8-week-old kittens affected with AMD received multiple intracranial injections of rAAV expressing the normal feline alpha-mannosidase cDNA. 74 The injections were performed at a time at which there was already clinical evidence of mild disease in the kittens. Physical and neurological examination after gene therapy revealed remarkable clinical improvement compared to untreated controls. At 18 weeks of age, the cats showed only mild signs of disease, while euthanasia was necessary in the untreated littermates because of the severity of neurological signs. One cat was followed out to 30 weeks of age when it developed clinical signs comparable to those seen at 18 weeks in untreated affected cats. Another treated cat never showed any disease progression from 18 weeks of life until euthanasia at 56 weeks of life. Magnetic resonance imaging also demonstrated improvement in brain myelination after treatment. Enzyme activity measured in whole brain sections was about 4% of normal. Storage lesions were markedly reduced throughout the whole brain, despite the fact that in situ hybridization showed mRNA only around injections tracks. 74 
Equine models
The horse is most commonly used as a model for osteoarthritis because the disease occurs naturally in this species. 75 Surprisingly though, virtually all of the gene transfer experiments have been performed in induced rather than natural models. 76, 77 While there are a number of naturally occurring diseases in the horse, to our knowledge only melanoma has been used in gene therapy experiments.
Melanoma occurs in 80% of gray horses older than 12 years of age. Interestingly, they are encapsulated and metastases occur infrequently early in the course of disease, which is in contrast to human malignant melanoma. 78 However, the histologic features and immunostaining results show extensive similarity to the human tumors, making the gray horse, like the dog, an attractive model to investigate treatments. 78 A total of 12 metastatic lesions on seven horses were injected with plasmid DNA coding for human interleukin-12. 79 No side effects of the treatment were observed. Three intralesional treatments spaced 2 weeks apart resulted in tumor size reduction, ranging from complete resolution to a slight increase in size in one animal. On average, the tumors decreased to 41% of their original size, whereas the untreated tumors increased slightly in size (107%) during the same time period. 79 Once the tumors had decreased in size and the treatment was discontinued, the tumors slowly grew larger but
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Bovine models
Cattle are rarely used for gene therapy experiments, probably because of their size and, thus, the expense of scaling up viral vectors or recombinant protein preparations. However, calves weigh about 30 -35 kg at birth, about the same as a child, making them a good model to address scaling up issues for therapies designed for older children. There are few animal models of urea cycle defects and to our knowledge there is no large animal model of citrullinemia, other than the established bovine model described below.
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Citrullinemia is a urea cycle disorder characterized by hyperammonemia and is caused by a nonsense mutation (C to T transition) in the gene coding for argininosuccinate synthetase in cattle. 81 While many of the clinical signs can be controlled by dietary restriction of proteins, additional illness or other stressors can easily result in hyperammonemia. 82 Citrullinemia in newborn Friesian calves is characterized by progressive neurological signs after their first feeding and subsequent death within the first few days of life. 80 Two neonatal calves were genotyped at birth and supplemented (arginine/benzoate) to prevent hyperammonemia and death. 83 At 8 days of life, the affected calves received an E1a-deleted adenovirus containing the human argininosuccinate synthetase cDNA intravenously. The effect of gene therapy was monitored both clinically and biochemically. Radioactively labeled ammonium chloride ( 15 N) was given every 6 h over a period of 2 days before and on days 2 -3 and 16 -17 after vector treatment. Before treatment, glutamine levels exceeded those of normal calves by up to three-fold. Radioactive glutamine and plasma citrulline concentrations decreased in both treated calves to virtually normal levels indicating normal urea synthesis, which lasted for at least 18 days after treatment.
Biochemical liver values were also measured to evaluate the safety of the vector. A week after administration of the adenovirus, both calves had elevated serum aspartate aminotransferase concentrations. All other liver parameters remained normal at all time points. Finally, there were no signs of inflammation by histological examination of the calves' liver 18 days after therapy, suggesting that the adenoviral therapy was safe. 83 Clearly, more studies will need to be performed, as only two calves received the vector and the last evaluation was done only 18 days after treatment.
Conclusions
Many of the gene transfer studies performed to date in large animals, especially sheep and non-human primates, have been done using normal animals and have been directed towards improving techniques. However, to fully understand and treat genetic diseases in human patients, the use of authentic animal models are required in studies that for ethical and practical reasons are not possible in humans. The large animals that have been used in gene therapy studies have been selected based on several factors: (1) the animals had similar clinical signs to affected humans, demonstrating similar genetic mechanisms underlying the diseases in both species; (2) their size, which was similar to that of neonates and children; and (3) their long lifespan, which should enable the detection of limitations to therapy. Thus, large animals provide the translational bridge from in vitro and mouse experiments to human patients. Many of the genetic disorders in large animal models that are available today are rare diseases but they often represent an entire class of diseases, such as lysosomal storage diseases, urea cycle defects, and neoplasia. Experiments in these models provide proof of principal for a given disease group and help to define the potential therapeutic efficacy and safety of gene transfer.
